Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM0306 + Lenalidomide in R/R B-NHL
NCT05771883Phase 2Unknown
- Sponsor
- ImmuneOnco
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of IMM0306S in B-cell non-Hodgkin lymphoma, sponsored by ImmuneOnco. Status: unknown.
02
Drugs
IMM0306S
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05771883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05771883.